Oxford PharmaGenesis bolsters board with first non-exec director appointment
Oxford PharmaGenesis, the health science communications consultant, said it has appointed former Shire and AstraZeneca executive Christopher Rains as its first non-executive director as the company expands its global footprint.
Rains is a former executive at Takeda, Shire and AstraZeneca and brings unparalleled knowledge and expertise of medical affairs. He has deep insight and understanding of the US healthcare and pharma/biotech sectors, said the company.
READ MORE: Oxford Biodynamics launches highly accurate prostate cancer screening test in UK and US
"I have had the pleasure of working with Oxford PharmaGenesis for many years and am thrilled to join the team as a Non-Executive Director," said Rains.
"This company has a track record of leadership in the medical affairs space, and I look forward to contributing to its continued success."
Oxford PharmaGenesis, established in 1998, provides services in strategic consultancy, publications, medical communications, events and meetings, digital, internal capability building and informatics and data science.
Specialist services include value demonstration, real-world evidence, rare diseases, patient engagement and policy.
It currently has more than 500 dedicated experts working in Europe, North America and Asia-Pacific.
